Clinical Trial Update: Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer [Phase 2]

View source ↗

Summary

Phase 2 study assessing bevacizumab in combination with FOLFIRI as second-line therapy for advanced, inoperable poorly differentiated neuroendocrine carcinoma w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroenteropancreatic Neuroendocrine Tumor
• Neuroendocrine Carcinoma

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Bevacizumab (bevacizumab)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)

Snippet

Sponsor: Hospices Civils de Lyon | Conditions: Neuroendocrine Carcinomas | Phase 2 | Status: COMPLETED